Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pioglitazone.

J M Lawrence1, J P Reckless

  • 1Department of Diabetes and Endocrinology, Royal United Hospital, Bath BA1 3NG, UK.

International Journal of Clinical Practice
|February 28, 2001
PubMed
Summary
This summary is machine-generated.

Pioglitazone, a PPAR-gamma agonist, effectively reduces insulin resistance in type 2 diabetes. Clinical trials show significant HbA1c reduction and improved lipids with good tolerability.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Two Cases of Puerperal Peritonitis.

Western journal of medicine and surgery·2024
Same author

Kondo quasiparticle dynamics observed by resonant inelastic x-ray scattering.

Nature communications·2022
Same author

A typology of North Sea oil and gas platforms.

Scientific reports·2022
Same author

Association of glucose metabolism and blood pressure during pregnancy with subsequent maternal blood pressure.

Journal of human hypertension·2021
Same author

Association between fear of hypoglycemia and physical activity in youth with type 1 diabetes: The SEARCH for diabetes in youth study.

Pediatric diabetes·2020
Same author

Socio-economic, demographic, and clinical correlates of poor glycaemic control within insulin regimens among children with Type 1 diabetes: the SEARCH for Diabetes in Youth  Study.

Diabetic medicine : a journal of the British Diabetic Association·2019
Same journal

RETRACTION: Prediction of Arrhythmia Recurrence after Atrial Fibrillation Ablation in Patients with Normal Anatomy of the Left Atrium.

International journal of clinical practice·2025
Same journal

Clinical Outcomes Based on the Attainment of Low-Density Lipoprotein Cholesterol Targets in Patients with Acute Coronary Syndrome in Real-World Practice.

International journal of clinical practice·2025
Same journal

Knowledge and Awareness of Osteoporosis: A Survey of Physical Therapy Providers in Saudi Arabia.

International journal of clinical practice·2024
Same journal

Efficacy and Safety of Pericapsular Nerve Group Block for Hip Fracture Surgery under Spinal Anesthesia: A Meta-Analysis.

International journal of clinical practice·2024
Same journal

The Role of Pharmaceutical Innovation in Clinical Practice Guidelines for Chronic Diseases.

International journal of clinical practice·2024
Same journal

Blood Features Associated with Viral Infection Severity: An Experience from COVID-19-Pandemic Patients Hospitalized in the Center of Iran, Yazd.

International journal of clinical practice·2024
See all related articles

Area of Science:

  • Pharmacology
  • Endocrinology
  • Metabolic Diseases

Background:

  • Pioglitazone is a thiazolidinedione drug.
  • It acts as a peroxisome proliferator-activated receptor gamma (PPAR-gamma) agonist.
  • PPAR-gamma activation modulates gene expression to decrease insulin resistance.

Purpose of the Study:

  • To evaluate the efficacy and tolerability of pioglitazone in patients with type 2 diabetes mellitus.
  • To assess pioglitazone's effectiveness as monotherapy and in combination with other antidiabetic agents.
  • To compare pioglitazone's safety profile with other thiazolidinediones, specifically regarding hepatotoxicity.

Main Methods:

  • Analysis of clinical trial data from over 4500 patients with type 2 diabetes.
  • Assessment of pioglitazone's impact on HbA1c levels.

Related Experiment Videos

  • Evaluation of pioglitazone's effects on lipid parameters.
  • Monitoring of side-effect incidence and tolerability.

    • Main Results:

    • Pioglitazone demonstrated significant reductions in HbA1c.
    • Favorable improvements in lipid parameters were observed.
    • The drug was well tolerated with a low incidence of side-effects.
    • No hepatotoxicity was associated with pioglitazone use, unlike troglitazone.

    Conclusions:

    • Pioglitazone is an effective treatment option for type 2 diabetes mellitus.
    • It offers benefits in glycemic control and lipid profiles.
    • Its favorable safety profile, particularly the absence of hepatotoxicity, makes it a valuable therapeutic choice.